(Reuters) – Gilead Sciences Inc has notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer – follicular lymphoma and small lymphocytic leukemia.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)
